




RealRate

PHARMACEUTICAL 2013

Furiex Pharmaceuticals Inc
Rank 130 of 218



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Furiex Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Furiex Pharmaceuticals Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Furiex Pharmaceuticals Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is 190%, being 31% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	37,783
Cost of Goods Sold	0
Intangible Assets	49,116
Liabilities, Current	22,239
Liabilities, Non-Current	34,919
Other Assets	7,738
Other Compr. Net Income	0
Other Expenses	2,608
Other Liabilities	0
Other Net Income	1.0
Other Revenues	40,508
Property and Equipment	118
Research and Development	69,505
Selling, General and Administrative Expense	11,261

Output Variable	Value in 1000 USD
Assets	94,755
Liabilities	57,158
Expenses	83,374
Revenues	40,508
Stockholders Equity	37,597
Net Income	-42,865
Comprehensive Net Income	-42,865
BaseVar	137,898
ECR before LimitedLiability	51%
Economic Capital Ratio	190%